Trial Outcomes & Findings for A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (NCT NCT01928394)
NCT ID: NCT01928394
Last Updated: 2024-12-27
Results Overview
The number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of treated participants.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
1163 participants
Primary outcome timeframe
60 months
Results posted on
2024-12-27
Participant Flow
1131 participants were treated in total for TNBC, GC, PC, SCLC, BC and OC.
Participant milestones
| Measure |
TNBC Arm N
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N - Pre-expansion
Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
|
SCLC Arm N-I Dose Level 2 - Pre-expansion
Small cell lung cancer (SCLC) treated participants in Pre-expansion cohort treated with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N Expansion
Small cell lung cancer (SCLC) expansion cohort participants: Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2- Expansion
Small cell lung cancer (SCLC) expansion cohort participants Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 1 -
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
BC Arm N
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c:
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Treatment Period
STARTED
|
18
|
3
|
18
|
59
|
3
|
49
|
52
|
18
|
3
|
18
|
30
|
98
|
61
|
147
|
96
|
3
|
55
|
78
|
92
|
104
|
41
|
43
|
42
|
|
Treatment Period
Transition
|
3
|
0
|
0
|
9
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
17
|
0
|
2
|
0
|
0
|
0
|
20
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period
Transition- Continued
|
0
|
0
|
3
|
0
|
0
|
3
|
6
|
0
|
1
|
1
|
0
|
0
|
17
|
0
|
2
|
0
|
0
|
0
|
1
|
19
|
0
|
0
|
0
|
|
Treatment Period
COMPLETED
|
0
|
0
|
0
|
3
|
0
|
6
|
3
|
0
|
0
|
0
|
0
|
5
|
6
|
8
|
8
|
1
|
5
|
7
|
22
|
8
|
1
|
1
|
3
|
|
Treatment Period
NOT COMPLETED
|
18
|
3
|
18
|
56
|
3
|
43
|
49
|
18
|
3
|
18
|
30
|
93
|
55
|
139
|
88
|
2
|
50
|
71
|
70
|
96
|
40
|
42
|
39
|
|
Follow-up Period
STARTED
|
15
|
3
|
18
|
50
|
3
|
49
|
52
|
16
|
3
|
18
|
30
|
81
|
61
|
145
|
96
|
3
|
55
|
58
|
92
|
104
|
41
|
43
|
42
|
|
Follow-up Period
COMPLETED
|
12
|
3
|
15
|
40
|
3
|
41
|
40
|
10
|
2
|
16
|
19
|
59
|
47
|
107
|
66
|
3
|
41
|
50
|
76
|
83
|
32
|
34
|
36
|
|
Follow-up Period
NOT COMPLETED
|
3
|
0
|
3
|
10
|
0
|
8
|
12
|
6
|
1
|
2
|
11
|
22
|
14
|
38
|
30
|
0
|
14
|
8
|
16
|
21
|
9
|
9
|
6
|
Reasons for withdrawal
| Measure |
TNBC Arm N
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N - Pre-expansion
Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
|
SCLC Arm N-I Dose Level 2 - Pre-expansion
Small cell lung cancer (SCLC) treated participants in Pre-expansion cohort treated with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N Expansion
Small cell lung cancer (SCLC) expansion cohort participants: Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2- Expansion
Small cell lung cancer (SCLC) expansion cohort participants Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 1 -
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
BC Arm N
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c:
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Treatment Period
Disease progression
|
17
|
2
|
12
|
48
|
3
|
25
|
38
|
16
|
3
|
11
|
22
|
73
|
38
|
118
|
59
|
1
|
43
|
56
|
50
|
71
|
30
|
31
|
31
|
|
Treatment Period
Study drug toxicity
|
1
|
1
|
3
|
3
|
0
|
9
|
7
|
1
|
0
|
5
|
2
|
3
|
7
|
5
|
12
|
0
|
3
|
3
|
12
|
15
|
4
|
7
|
4
|
|
Treatment Period
AE unrelated to study drug
|
0
|
0
|
2
|
3
|
0
|
5
|
1
|
0
|
0
|
2
|
0
|
12
|
6
|
13
|
6
|
1
|
1
|
6
|
3
|
5
|
1
|
1
|
0
|
|
Treatment Period
Participant request to stop therapy
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
0
|
0
|
3
|
2
|
1
|
2
|
4
|
0
|
1
|
3
|
1
|
1
|
3
|
1
|
3
|
|
Treatment Period
Participant withdrew consent
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
2
|
0
|
2
|
1
|
1
|
1
|
0
|
2
|
0
|
|
Treatment Period
Poor/non-compliance
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Treatment Period
other reason
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
|
Treatment Period
Maximum clinical benefit
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
0
|
2
|
0
|
0
|
|
Treatment Period
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Treatment Period
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Follow-up Period
Participant withdrew consent
|
3
|
0
|
1
|
4
|
0
|
2
|
5
|
1
|
0
|
0
|
5
|
8
|
2
|
12
|
7
|
0
|
5
|
3
|
2
|
7
|
4
|
6
|
2
|
|
Follow-up Period
Death
|
0
|
0
|
2
|
6
|
0
|
6
|
6
|
2
|
1
|
2
|
4
|
12
|
11
|
25
|
18
|
0
|
6
|
5
|
13
|
13
|
5
|
3
|
2
|
|
Follow-up Period
other reason
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
0
|
0
|
2
|
1
|
0
|
1
|
4
|
0
|
2
|
0
|
1
|
1
|
0
|
0
|
1
|
|
Follow-up Period
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
All Treated Participants
Baseline characteristics by cohort
| Measure |
TNBC Arm N
n=18 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
n=3 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
n=18 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
n=59 Participants
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
n=3 Participants
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
n=49 Participants
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
n=52 Participants
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
n=18 Participants
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
n=3 Participants
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
n=18 Participants
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
n=30 Participants
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N - Pre-expansion
n=98 Participants
Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
|
SCLC Arm N-I Dose Level 2 - Pre-expansion
n=61 Participants
Small cell lung cancer (SCLC) treated participants in Pre-expansion cohort treated with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N Expansion
n=147 Participants
Small cell lung cancer (SCLC) expansion cohort participants:Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2- Expansion
n=96 Participants
Small cell lung cancer (SCLC) expansion cohort participants Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2Wi
|
SCLC Arm N-I Dose Level 1 -
n=3 Participants
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
n=55 Participants
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
BC Arm N
n=78 Participants
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
n=92 Participants
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
n=104 Participants
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
n=41 Participants
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b:
n=43 Participants
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c:
n=42 Participants
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
Total
n=1131 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
53.3 Years
STANDARD_DEVIATION 11.9 • n=5 Participants • All Treated Participants
|
52.7 Years
STANDARD_DEVIATION 9.5 • n=7 Participants • All Treated Participants
|
49.1 Years
STANDARD_DEVIATION 9.0 • n=5 Participants • All Treated Participants
|
57.2 Years
STANDARD_DEVIATION 10.99 • n=4 Participants • All Treated Participants
|
67.0 Years
STANDARD_DEVIATION 9.54 • n=21 Participants • All Treated Participants
|
53.2 Years
STANDARD_DEVIATION 12.58 • n=8 Participants • All Treated Participants
|
56.4 Years
STANDARD_DEVIATION 13.40 • n=8 Participants • All Treated Participants
|
63.2 Years
STANDARD_DEVIATION 9.70 • n=24 Participants • All Treated Participants
|
58.3 Years
STANDARD_DEVIATION 9.87 • n=42 Participants • All Treated Participants
|
64.1 Years
STANDARD_DEVIATION 9.21 • n=42 Participants • All Treated Participants
|
62.1 Years
STANDARD_DEVIATION 11.51 • n=42 Participants • All Treated Participants
|
62.6 Years
STANDARD_DEVIATION 8.50 • n=42 Participants • All Treated Participants
|
63.9 Years
STANDARD_DEVIATION 9.94 • n=36 Participants • All Treated Participants
|
62.8 Years
STANDARD_DEVIATION 9.09 • n=36 Participants • All Treated Participants
|
63.7 Years
STANDARD_DEVIATION 9.06 • n=24 Participants • All Treated Participants
|
59.3 Years
STANDARD_DEVIATION 6.7 • n=135 Participants • All Treated Participants
|
60.1 Years
STANDARD_DEVIATION 7.74 • n=136 Participants • All Treated Participants
|
64.1 Years
STANDARD_DEVIATION 10.86 • n=44 Participants • All Treated Participants
|
63.9 Years
STANDARD_DEVIATION 9.54 • n=667 Participants • All Treated Participants
|
64.1 Years
STANDARD_DEVIATION 9.69 • n=12 Participants • All Treated Participants
|
56.7 Years
STANDARD_DEVIATION 11.1 • n=12 Participants • All Treated Participants
|
59.6 Years
STANDARD_DEVIATION 10.9 • n=12 Participants • All Treated Participants
|
58.7 Years
STANDARD_DEVIATION 12.2 • n=12 Participants • All Treated Participants
|
61.2 Years
STANDARD_DEVIATION 10.7 • n=11 Participants • All Treated Participants
|
|
Age, Customized
< 65
|
16 Participants
n=5 Participants • All Treated Participants
|
3 Participants
n=7 Participants • All Treated Participants
|
18 Participants
n=5 Participants • All Treated Participants
|
42 Participants
n=4 Participants • All Treated Participants
|
1 Participants
n=21 Participants • All Treated Participants
|
39 Participants
n=8 Participants • All Treated Participants
|
35 Participants
n=8 Participants • All Treated Participants
|
5 Participants
n=24 Participants • All Treated Participants
|
2 Participants
n=42 Participants • All Treated Participants
|
9 Participants
n=42 Participants • All Treated Participants
|
13 Participants
n=42 Participants • All Treated Participants
|
55 Participants
n=42 Participants • All Treated Participants
|
27 Participants
n=36 Participants • All Treated Participants
|
82 Participants
n=36 Participants • All Treated Participants
|
47 Participants
n=24 Participants • All Treated Participants
|
2 Participants
n=135 Participants • All Treated Participants
|
38 Participants
n=136 Participants • All Treated Participants
|
37 Participants
n=44 Participants • All Treated Participants
|
47 Participants
n=667 Participants • All Treated Participants
|
57 Participants
n=12 Participants • All Treated Participants
|
30 Participants
n=12 Participants • All Treated Participants
|
26 Participants
n=12 Participants • All Treated Participants
|
25 Participants
n=12 Participants • All Treated Participants
|
656 Participants
n=11 Participants • All Treated Participants
|
|
Age, Customized
>= 65 and < 75
|
1 Participants
n=5 Participants • All Treated Participants
|
0 Participants
n=7 Participants • All Treated Participants
|
0 Participants
n=5 Participants • All Treated Participants
|
15 Participants
n=4 Participants • All Treated Participants
|
1 Participants
n=21 Participants • All Treated Participants
|
8 Participants
n=8 Participants • All Treated Participants
|
12 Participants
n=8 Participants • All Treated Participants
|
12 Participants
n=24 Participants • All Treated Participants
|
1 Participants
n=42 Participants • All Treated Participants
|
7 Participants
n=42 Participants • All Treated Participants
|
14 Participants
n=42 Participants • All Treated Participants
|
34 Participants
n=42 Participants • All Treated Participants
|
27 Participants
n=36 Participants • All Treated Participants
|
51 Participants
n=36 Participants • All Treated Participants
|
39 Participants
n=24 Participants • All Treated Participants
|
1 Participants
n=135 Participants • All Treated Participants
|
17 Participants
n=136 Participants • All Treated Participants
|
31 Participants
n=44 Participants • All Treated Participants
|
34 Participants
n=667 Participants • All Treated Participants
|
29 Participants
n=12 Participants • All Treated Participants
|
10 Participants
n=12 Participants • All Treated Participants
|
14 Participants
n=12 Participants • All Treated Participants
|
12 Participants
n=12 Participants • All Treated Participants
|
370 Participants
n=11 Participants • All Treated Participants
|
|
Age, Customized
>= 75
|
1 Participants
n=5 Participants • All Treated Participants
|
0 Participants
n=7 Participants • All Treated Participants
|
0 Participants
n=5 Participants • All Treated Participants
|
2 Participants
n=4 Participants • All Treated Participants
|
1 Participants
n=21 Participants • All Treated Participants
|
2 Participants
n=8 Participants • All Treated Participants
|
5 Participants
n=8 Participants • All Treated Participants
|
1 Participants
n=24 Participants • All Treated Participants
|
0 Participants
n=42 Participants • All Treated Participants
|
2 Participants
n=42 Participants • All Treated Participants
|
3 Participants
n=42 Participants • All Treated Participants
|
9 Participants
n=42 Participants • All Treated Participants
|
7 Participants
n=36 Participants • All Treated Participants
|
14 Participants
n=36 Participants • All Treated Participants
|
10 Participants
n=24 Participants • All Treated Participants
|
0 Participants
n=135 Participants • All Treated Participants
|
0 Participants
n=136 Participants • All Treated Participants
|
10 Participants
n=44 Participants • All Treated Participants
|
11 Participants
n=667 Participants • All Treated Participants
|
18 Participants
n=12 Participants • All Treated Participants
|
1 Participants
n=12 Participants • All Treated Participants
|
3 Participants
n=12 Participants • All Treated Participants
|
5 Participants
n=12 Participants • All Treated Participants
|
105 Participants
n=11 Participants • All Treated Participants
|
|
Age, Customized
>= 65
|
2 Participants
n=5 Participants • All Treated Participants
|
0 Participants
n=7 Participants • All Treated Participants
|
0 Participants
n=5 Participants • All Treated Participants
|
17 Participants
n=4 Participants • All Treated Participants
|
2 Participants
n=21 Participants • All Treated Participants
|
10 Participants
n=8 Participants • All Treated Participants
|
17 Participants
n=8 Participants • All Treated Participants
|
13 Participants
n=24 Participants • All Treated Participants
|
1 Participants
n=42 Participants • All Treated Participants
|
9 Participants
n=42 Participants • All Treated Participants
|
17 Participants
n=42 Participants • All Treated Participants
|
43 Participants
n=42 Participants • All Treated Participants
|
34 Participants
n=36 Participants • All Treated Participants
|
65 Participants
n=36 Participants • All Treated Participants
|
49 Participants
n=24 Participants • All Treated Participants
|
1 Participants
n=135 Participants • All Treated Participants
|
17 Participants
n=136 Participants • All Treated Participants
|
41 Participants
n=44 Participants • All Treated Participants
|
45 Participants
n=667 Participants • All Treated Participants
|
47 Participants
n=12 Participants • All Treated Participants
|
11 Participants
n=12 Participants • All Treated Participants
|
17 Participants
n=12 Participants • All Treated Participants
|
17 Participants
n=12 Participants • All Treated Participants
|
475 Participants
n=11 Participants • All Treated Participants
|
|
Sex: Female, Male
Female
|
18 Participants
n=5 Participants • All treated Participants
|
3 Participants
n=7 Participants • All treated Participants
|
18 Participants
n=5 Participants • All treated Participants
|
14 Participants
n=4 Participants • All treated Participants
|
1 Participants
n=21 Participants • All treated Participants
|
15 Participants
n=8 Participants • All treated Participants
|
7 Participants
n=8 Participants • All treated Participants
|
5 Participants
n=24 Participants • All treated Participants
|
2 Participants
n=42 Participants • All treated Participants
|
8 Participants
n=42 Participants • All treated Participants
|
12 Participants
n=42 Participants • All treated Participants
|
37 Participants
n=42 Participants • All treated Participants
|
26 Participants
n=36 Participants • All treated Participants
|
61 Participants
n=36 Participants • All treated Participants
|
35 Participants
n=24 Participants • All treated Participants
|
1 Participants
n=135 Participants • All treated Participants
|
23 Participants
n=136 Participants • All treated Participants
|
24 Participants
n=44 Participants • All treated Participants
|
18 Participants
n=667 Participants • All treated Participants
|
23 Participants
n=12 Participants • All treated Participants
|
41 Participants
n=12 Participants • All treated Participants
|
43 Participants
n=12 Participants • All treated Participants
|
42 Participants
n=12 Participants • All treated Participants
|
477 Participants
n=11 Participants • All treated Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants • All treated Participants
|
0 Participants
n=7 Participants • All treated Participants
|
0 Participants
n=5 Participants • All treated Participants
|
45 Participants
n=4 Participants • All treated Participants
|
2 Participants
n=21 Participants • All treated Participants
|
34 Participants
n=8 Participants • All treated Participants
|
45 Participants
n=8 Participants • All treated Participants
|
13 Participants
n=24 Participants • All treated Participants
|
1 Participants
n=42 Participants • All treated Participants
|
10 Participants
n=42 Participants • All treated Participants
|
18 Participants
n=42 Participants • All treated Participants
|
61 Participants
n=42 Participants • All treated Participants
|
35 Participants
n=36 Participants • All treated Participants
|
86 Participants
n=36 Participants • All treated Participants
|
61 Participants
n=24 Participants • All treated Participants
|
2 Participants
n=135 Participants • All treated Participants
|
32 Participants
n=136 Participants • All treated Participants
|
54 Participants
n=44 Participants • All treated Participants
|
74 Participants
n=667 Participants • All treated Participants
|
81 Participants
n=12 Participants • All treated Participants
|
0 Participants
n=12 Participants • All treated Participants
|
0 Participants
n=12 Participants • All treated Participants
|
0 Participants
n=12 Participants • All treated Participants
|
654 Participants
n=11 Participants • All treated Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants • All Treated Participants
|
0 Participants
n=7 Participants • All Treated Participants
|
0 Participants
n=5 Participants • All Treated Participants
|
1 Participants
n=4 Participants • All Treated Participants
|
0 Participants
n=21 Participants • All Treated Participants
|
1 Participants
n=8 Participants • All Treated Participants
|
2 Participants
n=8 Participants • All Treated Participants
|
0 Participants
n=24 Participants • All Treated Participants
|
0 Participants
n=42 Participants • All Treated Participants
|
1 Participants
n=42 Participants • All Treated Participants
|
0 Participants
n=42 Participants • All Treated Participants
|
3 Participants
n=42 Participants • All Treated Participants
|
0 Participants
n=36 Participants • All Treated Participants
|
0 Participants
n=36 Participants • All Treated Participants
|
0 Participants
n=24 Participants • All Treated Participants
|
0 Participants
n=135 Participants • All Treated Participants
|
1 Participants
n=136 Participants • All Treated Participants
|
2 Participants
n=44 Participants • All Treated Participants
|
0 Participants
n=667 Participants • All Treated Participants
|
4 Participants
n=12 Participants • All Treated Participants
|
1 Participants
n=12 Participants • All Treated Participants
|
1 Participants
n=12 Participants • All Treated Participants
|
1 Participants
n=12 Participants • All Treated Participants
|
18 Participants
n=11 Participants • All Treated Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
10 Participants
n=5 Participants • All Treated Participants
|
3 Participants
n=7 Participants • All Treated Participants
|
9 Participants
n=5 Participants • All Treated Participants
|
41 Participants
n=4 Participants • All Treated Participants
|
2 Participants
n=21 Participants • All Treated Participants
|
29 Participants
n=8 Participants • All Treated Participants
|
35 Participants
n=8 Participants • All Treated Participants
|
16 Participants
n=24 Participants • All Treated Participants
|
3 Participants
n=42 Participants • All Treated Participants
|
13 Participants
n=42 Participants • All Treated Participants
|
28 Participants
n=42 Participants • All Treated Participants
|
63 Participants
n=42 Participants • All Treated Participants
|
47 Participants
n=36 Participants • All Treated Participants
|
97 Participants
n=36 Participants • All Treated Participants
|
55 Participants
n=24 Participants • All Treated Participants
|
2 Participants
n=135 Participants • All Treated Participants
|
26 Participants
n=136 Participants • All Treated Participants
|
59 Participants
n=44 Participants • All Treated Participants
|
38 Participants
n=667 Participants • All Treated Participants
|
73 Participants
n=12 Participants • All Treated Participants
|
26 Participants
n=12 Participants • All Treated Participants
|
29 Participants
n=12 Participants • All Treated Participants
|
32 Participants
n=12 Participants • All Treated Participants
|
736 Participants
n=11 Participants • All Treated Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
8 Participants
n=5 Participants • All Treated Participants
|
0 Participants
n=7 Participants • All Treated Participants
|
9 Participants
n=5 Participants • All Treated Participants
|
17 Participants
n=4 Participants • All Treated Participants
|
1 Participants
n=21 Participants • All Treated Participants
|
19 Participants
n=8 Participants • All Treated Participants
|
15 Participants
n=8 Participants • All Treated Participants
|
2 Participants
n=24 Participants • All Treated Participants
|
0 Participants
n=42 Participants • All Treated Participants
|
4 Participants
n=42 Participants • All Treated Participants
|
2 Participants
n=42 Participants • All Treated Participants
|
32 Participants
n=42 Participants • All Treated Participants
|
14 Participants
n=36 Participants • All Treated Participants
|
50 Participants
n=36 Participants • All Treated Participants
|
41 Participants
n=24 Participants • All Treated Participants
|
1 Participants
n=135 Participants • All Treated Participants
|
28 Participants
n=136 Participants • All Treated Participants
|
17 Participants
n=44 Participants • All Treated Participants
|
54 Participants
n=667 Participants • All Treated Participants
|
27 Participants
n=12 Participants • All Treated Participants
|
14 Participants
n=12 Participants • All Treated Participants
|
13 Participants
n=12 Participants • All Treated Participants
|
9 Participants
n=12 Participants • All Treated Participants
|
377 Participants
n=11 Participants • All Treated Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=135 Participants • All Treated Participnats
|
0 Participants
n=136 Participants • All Treated Participnats
|
0 Participants
n=44 Participants • All Treated Participnats
|
0 Participants
n=667 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
1 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
1 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
1 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
2 Participants
n=36 Participants • All Treated Participnats
|
1 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=135 Participants • All Treated Participnats
|
0 Participants
n=136 Participants • All Treated Participnats
|
1 Participants
n=44 Participants • All Treated Participnats
|
1 Participants
n=667 Participants • All Treated Participnats
|
4 Participants
n=12 Participants • All Treated Participnats
|
2 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
1 Participants
n=12 Participants • All Treated Participnats
|
18 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=135 Participants • All Treated Participnats
|
0 Participants
n=136 Participants • All Treated Participnats
|
0 Participants
n=44 Participants • All Treated Participnats
|
0 Participants
n=667 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
1 Participants
n=5 Participants • All Treated Participnats
|
3 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
1 Participants
n=8 Participants • All Treated Participnats
|
1 Participants
n=8 Participants • All Treated Participnats
|
1 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=42 Participants • All Treated Participnats
|
4 Participants
n=42 Participants • All Treated Participnats
|
3 Participants
n=42 Participants • All Treated Participnats
|
1 Participants
n=36 Participants • All Treated Participnats
|
7 Participants
n=36 Participants • All Treated Participnats
|
5 Participants
n=24 Participants • All Treated Participnats
|
1 Participants
n=135 Participants • All Treated Participnats
|
0 Participants
n=136 Participants • All Treated Participnats
|
4 Participants
n=44 Participants • All Treated Participnats
|
3 Participants
n=667 Participants • All Treated Participnats
|
4 Participants
n=12 Participants • All Treated Participnats
|
1 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
2 Participants
n=12 Participants • All Treated Participnats
|
46 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
White
|
14 Participants
n=5 Participants • All Treated Participnats
|
3 Participants
n=7 Participants • All Treated Participnats
|
17 Participants
n=5 Participants • All Treated Participnats
|
56 Participants
n=4 Participants • All Treated Participnats
|
3 Participants
n=21 Participants • All Treated Participnats
|
46 Participants
n=8 Participants • All Treated Participnats
|
50 Participants
n=8 Participants • All Treated Participnats
|
16 Participants
n=24 Participants • All Treated Participnats
|
3 Participants
n=42 Participants • All Treated Participnats
|
16 Participants
n=42 Participants • All Treated Participnats
|
23 Participants
n=42 Participants • All Treated Participnats
|
91 Participants
n=42 Participants • All Treated Participnats
|
60 Participants
n=36 Participants • All Treated Participnats
|
134 Participants
n=36 Participants • All Treated Participnats
|
87 Participants
n=24 Participants • All Treated Participnats
|
2 Participants
n=135 Participants • All Treated Participnats
|
54 Participants
n=136 Participants • All Treated Participnats
|
72 Participants
n=44 Participants • All Treated Participnats
|
87 Participants
n=667 Participants • All Treated Participnats
|
90 Participants
n=12 Participants • All Treated Participnats
|
37 Participants
n=12 Participants • All Treated Participnats
|
43 Participants
n=12 Participants • All Treated Participnats
|
38 Participants
n=12 Participants • All Treated Participnats
|
1042 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=135 Participants • All Treated Participnats
|
0 Participants
n=136 Participants • All Treated Participnats
|
0 Participants
n=44 Participants • All Treated Participnats
|
0 Participants
n=667 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=11 Participants • All Treated Participnats
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=7 Participants • All Treated Participnats
|
0 Participants
n=5 Participants • All Treated Participnats
|
0 Participants
n=4 Participants • All Treated Participnats
|
0 Participants
n=21 Participants • All Treated Participnats
|
1 Participants
n=8 Participants • All Treated Participnats
|
1 Participants
n=8 Participants • All Treated Participnats
|
0 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=42 Participants • All Treated Participnats
|
2 Participants
n=42 Participants • All Treated Participnats
|
2 Participants
n=42 Participants • All Treated Participnats
|
0 Participants
n=36 Participants • All Treated Participnats
|
4 Participants
n=36 Participants • All Treated Participnats
|
3 Participants
n=24 Participants • All Treated Participnats
|
0 Participants
n=135 Participants • All Treated Participnats
|
1 Participants
n=136 Participants • All Treated Participnats
|
1 Participants
n=44 Participants • All Treated Participnats
|
1 Participants
n=667 Participants • All Treated Participnats
|
6 Participants
n=12 Participants • All Treated Participnats
|
1 Participants
n=12 Participants • All Treated Participnats
|
0 Participants
n=12 Participants • All Treated Participnats
|
1 Participants
n=12 Participants • All Treated Participnats
|
24 Participants
n=11 Participants • All Treated Participnats
|
PRIMARY outcome
Timeframe: 60 monthsPopulation: All Treated Participants
The number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of treated participants.
Outcome measures
| Measure |
TNBC Arm N
n=18 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
n=3 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
n=18 Participants
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
n=59 Participants
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
n=3 Participants
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
n=49 Participants
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
n=52 Participants
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
n=18 Participants
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
n=3 Participants
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
n=18 Participants
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
n=30 Participants
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N - Pre-expansion
n=98 Participants
Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
|
SCLC Arm N-I Dose Level 2 - Pre-expansion
n=61 Participants
Small cell lung cancer (SCLC) treated participants in Pre-expansion cohort treated with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N Expansion
n=147 Participants
Small cell lung cancer (SCLC) expansion cohort participants:Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2- Expansion
n=96 Participants
Small cell lung cancer (SCLC) expansion cohort participants Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2Wi
|
SCLC Arm N-I Dose Level 1 -
n=3 Participants
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
n=55 Participants
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
SCLC Arm N- All Treated
n=245 Participants
Small cell lung cancer (SCLC) for all treated participants with Nivolumab 3 mg/kg Q2W
|
SCLC Arm N-I Dose Level 2 - All Treated
n=157 Participants
Small cell lung cancer (SCLC) all treated participants with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses
|
BC Arm N
n=78 Participants
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
n=92 Participants
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
n=104 Participants
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
n=41 Participants
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b:
n=43 Participants
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c:
n=42 Participants
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Objective Response Rate ( ORR )
|
5.6 Percentage of Participants
Interval 0.1 to 27.3
|
0.0 Percentage of Participants
Interval 0.0 to 70.8
|
0.0 Percentage of Participants
Interval 0.0 to 18.5
|
11.9 Percentage of Participants
Interval 4.9 to 22.9
|
0.0 Percentage of Participants
Interval 0.0 to 70.8
|
24.5 Percentage of Participants
Interval 13.3 to 38.9
|
7.7 Percentage of Participants
Interval 2.1 to 18.5
|
0.0 Percentage of Participants
Interval 0.0 to 18.5
|
0.0 Percentage of Participants
Interval 0.0 to 70.8
|
0.0 Percentage of Participants
Interval 0.0 to 18.5
|
6.7 Percentage of Participants
Interval 0.8 to 22.1
|
13.3 Percentage of Participants
Interval 7.3 to 21.6
|
26.2 Percentage of Participants
Interval 15.8 to 39.1
|
11.6 Percentage of Participants
Interval 6.9 to 17.9
|
21.9 Percentage of Participants
Interval 14.1 to 31.5
|
33.3 Percentage of Participants
Interval 0.8 to 90.6
|
18.2 Percentage of Participants
Interval 9.1 to 30.9
|
11.8 Percentage of Participants
Interval 8.1 to 16.6
|
22.3 Percentage of Participants
Interval 16.0 to 29.6
|
25.6 Percentage of Participants
Interval 16.4 to 36.8
|
38.0 Percentage of Participants
Interval 28.1 to 48.8
|
26.9 Percentage of Participants
Interval 18.7 to 36.5
|
12.2 Percentage of Participants
Interval 4.1 to 26.2
|
7.0 Percentage of Participants
Interval 1.5 to 19.1
|
9.5 Percentage of Participants
Interval 2.7 to 22.6
|
Adverse Events
TNBC Arm N
Serious events: 9 serious events
Other events: 18 other events
Deaths: 17 deaths
TNBC Arm N-I Dose Level 1
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
TNBC Arm N-I Dose Level 2
Serious events: 11 serious events
Other events: 17 other events
Deaths: 18 deaths
GC Arm N
Serious events: 32 serious events
Other events: 58 other events
Deaths: 53 deaths
GC Arm N-I Dose Level 1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 3 deaths
GC Arm N-I Dose Level 2
Serious events: 37 serious events
Other events: 47 other events
Deaths: 42 deaths
GC Arm N-I Dose Level 2b
Serious events: 34 serious events
Other events: 49 other events
Deaths: 50 deaths
PC Arm N
Serious events: 10 serious events
Other events: 18 other events
Deaths: 18 deaths
PC Arm N-I Dose Level 1
Serious events: 3 serious events
Other events: 3 other events
Deaths: 3 deaths
PC Arm N-I Dose Level 2
Serious events: 11 serious events
Other events: 17 other events
Deaths: 18 deaths
PC Arm N-I Dose Level 2d
Serious events: 16 serious events
Other events: 29 other events
Deaths: 24 deaths
SCLC Arm N
Serious events: 129 serious events
Other events: 226 other events
Deaths: 212 deaths
SCLC Arm N-I Dose Level 2
Serious events: 111 serious events
Other events: 147 other events
Deaths: 136 deaths
SCLC Arm N-I Dose Level 1
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
SCLC Arm N-I Dose Level 2b
Serious events: 32 serious events
Other events: 53 other events
Deaths: 45 deaths
BC Arm N
Serious events: 41 serious events
Other events: 77 other events
Deaths: 60 deaths
BC Arm N-I Dose Level 2
Serious events: 62 serious events
Other events: 85 other events
Deaths: 54 deaths
BC Arm N-I Dose Level 2b
Serious events: 72 serious events
Other events: 100 other events
Deaths: 82 deaths
OC Arm N-I Dose Level 2
Serious events: 24 serious events
Other events: 38 other events
Deaths: 33 deaths
OC Arm N-I Dose Level 2b
Serious events: 31 serious events
Other events: 40 other events
Deaths: 37 deaths
OC Arm N-I Dose Level 2c
Serious events: 29 serious events
Other events: 41 other events
Deaths: 34 deaths
Serious adverse events
| Measure |
TNBC Arm N
n=18 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
n=3 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
n=18 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
n=59 participants at risk
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
n=3 participants at risk
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
n=49 participants at risk
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
n=52 participants at risk
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
n=18 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
n=3 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
n=18 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
n=30 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N
n=245 participants at risk
Small cell lung cancer (SCLC) pre-expansion and expansion cohort participants: Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2
n=157 participants at risk
Small cell lung cancer (SCLC) pre-expansion and expansion cohort participants: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2Wi
|
SCLC Arm N-I Dose Level 1
n=3 participants at risk
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
n=55 participants at risk
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
BC Arm N
n=78 participants at risk
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
n=92 participants at risk
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
n=104 participants at risk
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
n=41 participants at risk
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b
n=43 participants at risk
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c
n=42 participants at risk
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Dysfunctional uterine bleeding
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
8/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Cutaneous lupus erythematosus
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Pemphigoid
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Embolism
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Hypertension
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Oesophageal fistula
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Prerenal failure
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Renal disorder
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Urethral obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Blood loss anaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Atrioventricular block complete
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Cardiac tamponade
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Myocarditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Palpitations
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Pericardial haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Sinus tachycardia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Tachycardia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hypophysitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hypopituitarism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Inappropriate antidiuretic hormone secretion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Thyroiditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Diplopia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Endocrine ophthalmopathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Eye pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Vision blurred
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Autoimmune colitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Colonic fistula
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
5/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.9%
10/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Duodenal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastritis haemorrhagic
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Immune-mediated enterocolitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Intestinal pseudo-obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Oesophageal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Adverse event
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Asthenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Chest pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Cyst
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Disease progression
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Fatigue
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Gait disturbance
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
General physical health deterioration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Malaise
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Oedema peripheral
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Pyrexia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Sudden death
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Systemic inflammatory response syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Autoimmune hepatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Drug-induced liver injury
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Hepatic failure
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Hepatic pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Hepatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Steatohepatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Immune system disorders
Haemophagocytic lymphohistiocytosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Abdominal sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Arthritis infective
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Aspergillus infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Bacterial sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Biliary sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Candida infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Cellulitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Cystitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Device related infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Diarrhoea infectious
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Encephalitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Kidney infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Lung infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Meningitis aseptic
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Peritoneal abscess
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Pneumonia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.3%
13/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Respiratory tract infection viral
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Salmonellosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Sepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Sinusitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Skin infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Systemic candida
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Urosepsis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Vascular device infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Viral diarrhoea
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Anaesthetic complication neurological
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Gastrointestinal stoma complication
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Radiation injury
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.2%
4/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Amylase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood creatinine increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Lipase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Liver function test increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Platelet count decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Transaminases increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
White blood cell count decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Alkalosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Dehydration
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperammonaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Type 3 diabetes mellitus
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Bone lesion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Polymyositis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenocarcinoma
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Infected neoplasm
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphangiosis carcinomatosa
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
9/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
7/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
54/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.3%
35/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.6%
13/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.1%
13/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
10/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to meninges
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm progression
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraneoplastic syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Cerebral ischaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Dizziness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Facial paralysis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Headache
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Limbic encephalitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Myasthenic syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Paraparesis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Posterior reversible encephalopathy syndrome
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Presyncope
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Radiculopathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Seizure
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Syncope
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Product Issues
Device leakage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Delirium
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Substance-induced psychotic disorder
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Haemorrhage urinary tract
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Hypotension
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Jugular vein thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Poor venous access
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Superior vena cava syndrome
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Venous thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
Other adverse events
| Measure |
TNBC Arm N
n=18 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 1
n=3 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
TNBC Arm N-I Dose Level 2
n=18 participants at risk
Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N
n=59 participants at risk
Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 1
n=3 participants at risk
Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
GC Arm N-I Dose Level 2
n=49 participants at risk
Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
|
GC Arm N-I Dose Level 2b
n=52 participants at risk
Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N
n=18 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
|
PC Arm N-I Dose Level 1
n=3 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2
n=18 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
PC Arm N-I Dose Level 2d
n=30 participants at risk
Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
|
SCLC Arm N
n=245 participants at risk
Small cell lung cancer (SCLC) pre-expansion and expansion cohort participants: Nivolumab monotherapy (3 mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2
n=157 participants at risk
Small cell lung cancer (SCLC) pre-expansion and expansion cohort participants: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2Wi
|
SCLC Arm N-I Dose Level 1
n=3 participants at risk
Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W
|
SCLC Arm N-I Dose Level 2b
n=55 participants at risk
Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
BC Arm N
n=78 participants at risk
Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W
|
BC Arm N-I Dose Level 2
n=92 participants at risk
Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
BC Arm N-I Dose Level 2b
n=104 participants at risk
Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2
n=41 participants at risk
Ovarian cancer (OC) participants:
Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2b
n=43 participants at risk
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W
|
OC Arm N-I Dose Level 2c
n=42 participants at risk
Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Immune system disorders
Seasonal allergy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Bacterial disease carrier
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Bronchitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Candida infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.5%
8/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
9/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Anaemia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
32.2%
19/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
24.5%
12/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
32.7%
17/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
44.4%
8/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.1%
37/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.6%
26/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.2%
10/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
34.6%
27/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.6%
18/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
28.8%
30/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.3%
10/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.0%
8/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.9%
6/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Palpitations
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
5/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hyperthyroidism
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.2%
4/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.0%
22/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
9/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.5%
13/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hypogonadism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Hypothyroidism
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
6/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
14/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
24/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.9%
6/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
9/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.2%
14/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.4%
16/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.1%
7/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.3%
10/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.0%
8/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Inappropriate antidiuretic hormone secretion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Thyroid disorder
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Endocrine disorders
Thyroiditis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Diplopia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Dry eye
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Eye discharge
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Keratitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Photopsia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Eye disorders
Vision blurred
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.5%
6/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal distension
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
6/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
7/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal pain
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
28.8%
17/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.3%
9/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.9%
17/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.1%
19/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.9%
6/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.9%
14/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
15/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.2%
21/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
41.5%
17/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
44.2%
19/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.2%
11/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
5/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.6%
8/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.2%
4/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
7/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
7/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
6/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
9/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Constipation
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.4%
15/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.4%
9/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.8%
16/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.0%
49/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.7%
34/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.8%
12/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.5%
16/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.7%
19/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.9%
28/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
9/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
32.6%
14/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.8%
10/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Diarrhoea
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
61.1%
11/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
28.8%
17/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.6%
15/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.4%
8/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
55.6%
10/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
70.0%
21/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
54/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
28.7%
45/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.9%
17/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.8%
17/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
47.8%
44/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
36.5%
38/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.7%
13/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
44.2%
19/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.1%
16/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Dry mouth
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
7/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
12/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.0%
11/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.5%
13/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
5/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
9/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.0%
13/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
8/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Nausea
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
35.6%
21/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
100.0%
3/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.6%
15/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.9%
14/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
55.6%
10/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
40.0%
12/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.4%
55/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
24.2%
38/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.9%
17/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
29.5%
23/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.2%
25/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.7%
33/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
39.0%
16/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
48.8%
21/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
42.9%
18/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Steatorrhoea
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.6%
7/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Tongue disorder
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.5%
18/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.4%
9/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.8%
16/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
50.0%
15/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.1%
37/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.6%
26/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.0%
11/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
13/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.7%
19/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.3%
19/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
9/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.2%
13/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.2%
11/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Asthenia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
5/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
7/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.4%
28/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.1%
19/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.8%
12/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Chest pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.3%
13/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Chills
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
8/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.0%
11/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Early satiety
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Face oedema
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Facial pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Fatigue
|
44.4%
8/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
54.2%
32/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
44.9%
22/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
53.8%
28/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
61.1%
11/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
72.2%
13/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
73.3%
22/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
36.3%
89/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
42.7%
67/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
45.5%
25/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
59.0%
46/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
39.1%
36/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
50.0%
52/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
51.2%
21/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
55.8%
24/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
64.3%
27/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Gait disturbance
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
General physical health deterioration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Hyperpyrexia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Influenza like illness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Localised oedema
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Malaise
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Mucosal inflammation
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Nodule
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
11/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Oedema
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Oedema peripheral
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
5/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.0%
9/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
18/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.1%
19/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
13/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.6%
18/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.2%
22/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.1%
7/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.6%
8/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
5/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
10/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.0%
12/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
12/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Peripheral swelling
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Pyrexia
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.1%
16/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.4%
10/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.9%
14/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
40.0%
12/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
14/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.7%
20/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.1%
11/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.5%
29/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
17/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
9/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.9%
9/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
7/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Temperature intolerance
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Tenderness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
General disorders
Thirst
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Immune system disorders
Hypersensitivity
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Cellulitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Conjunctivitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Helicobacter gastritis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Herpes virus infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Hordeolum
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Mucosal infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Nasopharyngitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Pharyngitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Pneumonia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Respiratory tract infection
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Sinusitis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Skin infection
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Tonsillitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Upper respiratory tract infection
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
12/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
9/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
12/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.9%
14/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.9%
10/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
12/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.0%
8/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Accidental device ingestion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
11/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
14/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Post procedural inflammation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Activated partial thromboplastin time
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Alanine aminotransferase increased
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
6/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.4%
11/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.6%
26/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.7%
20/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
15/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.2%
20/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
9/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.3%
4/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.4%
9/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Amylase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
14/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
18/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
9/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Aspartate aminotransferase increased
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.6%
8/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.4%
9/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.0%
27/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.9%
25/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.0%
11/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.3%
19/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.5%
8/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.0%
6/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.8%
10/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood alkaline phosphatase increased
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
6/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
15/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.3%
13/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
8/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood calcium decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood creatinine increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
10/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.5%
16/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
8/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.4%
16/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood lactic acid increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood pressure increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood urea increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Blood uric acid increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
C-reactive protein increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Hepatic enzyme increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
International normalised ratio increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Lipase increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.6%
21/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
15/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.9%
14/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
9/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.3%
4/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Liver function test increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Platelet count decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.6%
11/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Transaminases increased
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Troponin increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Weight decreased
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.6%
8/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.4%
8/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
15/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
24/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.7%
7/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.0%
23/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.4%
16/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.3%
4/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
5/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
Weight increased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Investigations
White blood cell count decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Decreased appetite
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
35.6%
21/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
28.6%
14/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
36.5%
19/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
36.7%
11/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.3%
67/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.8%
50/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.3%
15/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.9%
14/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.8%
21/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
34.6%
36/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
24.4%
10/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.6%
11/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.0%
13/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
9/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.7%
14/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
15/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
8/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.1%
18/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.5%
6/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.0%
26/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
10/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
8/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
6/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
12/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.0%
6/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
8/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
18/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.3%
13/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.6%
7/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.8%
19/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.8%
17/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.7%
7/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.0%
11/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.0%
8/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
6/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.2%
4/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
7/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.5%
38/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.1%
19/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
5/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
5/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.9%
10/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
6/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.5%
38/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
18/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.4%
9/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.9%
21/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.0%
12/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.3%
18/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.6%
8/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
7/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.6%
11/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.2%
10/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
30/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.2%
16/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.8%
17/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.7%
20/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.2%
22/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.6%
8/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.0%
11/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.7%
9/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
6/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.5%
6/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.3%
13/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
11/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.8%
10/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Amnesia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Ataxia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Dizziness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
5/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
12/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
18/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.5%
8/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
9/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Dysaesthesia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
10/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.5%
6/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Freezing phenomenon
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Headache
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.3%
7/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.6%
21/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.9%
25/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.1%
11/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
15/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.2%
11/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Hypogeusia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Lethargy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Memory impairment
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Migraine
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Mononeuropathy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Paraesthesia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.6%
7/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
4/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Syncope
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Agitation
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
66.7%
2/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Anxiety
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
11/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
8/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
7/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
10/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Depression
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.7%
9/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Insomnia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.6%
8/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
7/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.0%
22/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
18/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.3%
8/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.0%
12/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
14/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Irritability
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Psychiatric disorders
Libido decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.2%
15/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.8%
9/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.6%
11/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Micturition frequency decreased
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.2%
5/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Breast haemorrhage
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Gynaecomastia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Nipple exudate bloody
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.8%
5/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.9%
7/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
8/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.1%
12/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.7%
8/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.0%
44/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.5%
40/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.3%
15/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
24.4%
19/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
18.5%
17/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.3%
18/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
6/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.4%
9/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
10/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.3%
9/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.3%
9/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
23.3%
7/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.0%
49/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.6%
26/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.5%
14/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
25.6%
20/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.6%
18/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.5%
14/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
19.5%
8/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.3%
4/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
14/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
10.0%
3/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
3/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
8/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
4/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.3%
4/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.3%
4/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
7/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Nasal dryness
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive airways disorder
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
5/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.6%
5/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
15/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
10/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.3%
4/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
5/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
6/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary pain
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
3/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.4%
5/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.6%
7/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Sputum discoloured
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.6%
4/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
4/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
4/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.7%
8/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Dermatitis exfoliative generalised
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.3%
13/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
8/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.1%
11/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.5%
6/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.4%
15/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.2%
5/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Eczema
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.2%
3/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
3/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
3/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.1%
2/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
3/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.6%
7/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.2%
4/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
22.0%
13/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
26.5%
13/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
30.8%
16/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
38.9%
7/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
36.7%
11/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.9%
34/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.4%
43/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.5%
8/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
35.9%
28/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
34.8%
32/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
32.7%
34/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
41.5%
17/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
27.9%
12/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.4%
9/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Pruritus generalised
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Rash
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
6/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
8.5%
5/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
20.4%
10/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
17.3%
9/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.7%
3/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
40.0%
12/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
15/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
15.9%
25/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.7%
7/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.7%
6/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
15/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
12.5%
13/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.6%
5/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.5%
4/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
3/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
33.3%
1/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
8/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.5%
6/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
13.3%
4/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
12/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.6%
23/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
9.1%
5/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
24.4%
19/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
16.3%
15/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
21.2%
22/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
31.7%
13/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
14.3%
6/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.5%
3/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.96%
1/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Skin mass
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.82%
2/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Embolism
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.8%
6/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Haematoma
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
1/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Hot flush
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.7%
1/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.41%
1/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.3%
2/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.0%
3/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.1%
3/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Hypertension
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.4%
2/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.0%
1/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.7%
2/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.9%
7/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.5%
4/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.6%
2/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.2%
2/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
2/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.7%
2/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.4%
1/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Hypotension
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.8%
4/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
6.1%
3/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.8%
2/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
3.3%
1/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
11/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.5%
7/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.8%
1/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.1%
4/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.4%
5/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
5/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
7.3%
3/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.3%
1/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Lymphoedema
|
11.1%
2/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
2.6%
2/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.9%
2/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
4.8%
2/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.9%
1/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.64%
1/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
|
Vascular disorders
Venous thrombosis
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
5.6%
1/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/59 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/49 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/52 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/18 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/30 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/245 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/157 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/3 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/55 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/78 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
1.1%
1/92 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/104 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/41 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/43 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
0.00%
0/42 • Includes events reported between first dose and 30 days (AEs) or 100 days (SAEs) after last dose of study therapy
|
Additional Information
Bristol-Myers Squibb Study Director
Bristol-Myers Squibb
Phone: Please email
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60